Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Bosco & Crossy's stock picks,talk area -- Ignore unavailable to you. Want to Upgrade?

To: PuddleGlum who wrote (3344)	5/7/2003 5:32:30 PM
From: Crossy	Read Replies (1) \| Respond to of 37387

PuddleGlum, great you are in here. It's a real gem in the making. I plan to accumulate on weakness. I doubled my position recently taking advantage of sub $0.50 prices.. Volume 7x normal is typically news driven. Sit back, relax - and don't chase a stock now. The story will soon unfold but I think we are quite early here. No "rush" to do anything will be required. I just noticed that the PR looks even better after I delved deeper. Especially this looks too good to be true, at least to me: "The dosage required for surgical patients is usually many times higher than the use in treating anemia associated with chronic renal failure. The approval will expand the market opportunities for Dragon's EPO in the existing approved countries. "We are confident that Dragon's competitive cost advantages, its clinically tested EPO at proper dosages for surgery indication and the distribution network in 136 countries built by our licensees will enable Dragon to capture the additional market opportunities as a result of the new approval." said, Dr. Wick, President of Dragon. "In addition to the approved indications for use in the treatment of anemia related to chronic renal failure and surgical patients, we are also actively pursuing clinical trials for cancer radio and chemotherapy patients in China. Dragon intends to submit a market approval application to the Chinese SDA in 2003 together with the new 10000 IU dosage that will be used in association with this new indication." It seems that the new indication (EPO for surgical patients) will not only expand the addressable market, it will also increase per treatment dosage because for surgical patients 6000 IU will be used (times more than for chronic renal failure). That must be at least 2 times of the latter's dosage. And I guess there are way more surgical interventions going on where EPO could be useful than there are patients with chronic renal disease - despite the fact that the latter is a more "stable" market demand.. The next indication "radiation therapy adjuvant" looks even better given the 10.000 IU dosage indicated here.. Maybe recurring sales could go up more than 50% ? rgrds CROSSY